皓元医药：9月26日召开董事会会议

Group 1 - The core point of the article is that Haoyuan Pharmaceutical announced a board meeting to discuss adjustments to the restricted stock incentive plan for 2023 and 2025, indicating strategic financial management [1] - The company's revenue composition for 2024 is heavily focused on research and experimental development, accounting for 99.27%, with other businesses making up only 0.73% [1] - As of the report, Haoyuan Pharmaceutical has a market capitalization of 16.8 billion yuan [1] Group 2 - The article highlights a significant growth trend in a new type of insurance product, which has seen a 33-fold increase over five years, attracting interest from over 30 insurance companies [1]